SANDOZ

Date: March 2026

DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION

Afqlir ▼ (aflibercept) 40 mg/ml Solution for injection in pre-filled syringe

Interim Supply of Stock Containing the Danish Version of the Patient Information Leaflet

Dear Healthcare Professional / Wholesaler

Summary: Sandoz is currently distributing the Patient Information Leaflet of Afqlir 40 mg/ml solution for injection in pre-filled syringe outside of the pack to address supply constraints in the UK

To ensure continuity in supply, Sandoz has obtained approval from the MHRA to distribute Afqlir 40 mg/ml solution for injection in pre-filled syringe intended for Denmark (Batch Numbers VRW43G and VRW48F) which is expected to be on the UK market from 15 May 2026 and will be accompanied by the UK Patient Information Leaflet provided separately outside of the pack.

Please note the following:

- **This product is considered licensed in the UK.**
- **The product from Denmark is manufactured according to the same manufacturing process and quality controls as the UK product.**
- **An interim delay in the supply of Afqlir 40 mg/ml solution for injection in pre-filled syringe has caused supply constraints in the UK.**
- **To ensure adequate availability of 40 mg/ml solution for injection in pre-filled syringe in the UK until continual supply is reinstated, Afqlir originally destined for Denmark (batch number and expiry date shown below), have been repurposed for the UK.**
- **The only differences are the packaging (which includes the outer box, label and Patient Information Leaflet).**
- **The Danish Patient Information Leaflet can be discarded.**
- **Please refer patients to the UK PIL supplied with the Danish packs.**
- **Please be assured that there has been no change to the medicine inside the pack.**
- **Carefully check the differences and the batch numbers and expiry dates below, and if they match, please reassure patients that this product is the same as their usual UK product. If the numbers do not match, please follow your medicines falsification protocol.**
- **MHRA has approved this product under a labelling exemption to allow specific batches intended for the Danish market to be supplied in the UK.**

SANDOZ

Please ensure all relevant staff are made aware of the content of this letter and that the information is communicated to the patients.

Background

Following an interim delay in supply of Afqlir 40 mg/ml solution for injection in pre-filled syringe in the UK, the MHRA have agreed that Sandoz can supply packs originally intended for Denmark, while providing the UK patient information leaflet separately. This is to ensure that adequate supply of Afqlir is available for the UK until supply has been reinstated. Therefore, the packs are individually placed in clear plastic bags with the UK Patient Information Leaflet and a copy of this direct healthcare professional communication inserted.

The Batch Number of the Packs are as Follows:

Product	Batch Numbers	Expiry Date
Afqlir 40 mg/ml solution for injection in pre-filled syringe	VRW43G, VRW48F	31-JUL-2028

The MHRA has agreed that Sandoz will make wholesalers and healthcare professionals who are likely to dispense the product aware of this in case a patient or carer is concerned by this difference. We will also notify the NHS Commercial Medicines Unit and share a copy of this letter with them via email for distribution.

If a patient or caregiver contacts you with concerns, carefully check the batch numbers and expiry dates as stated above, and if they match, please reassure patients that the new Patient Information Leaflet is provided separately and that there has been no change to the medicine inside the pack.

If you require additional copies of this letter, please contact mi.uk@sandoz.com.

Call for Reporting

Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme.

Please report:

- all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason
- all suspected ADRs associated with new drugs and vaccines identified by the black triangle ▼

You can report via:

- the Yellow Card website

- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) for healthcare professionals

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, timing onset, treatment dates, and product brand name.

Adverse events should also be reported to Sandoz via adverse.event.uk@sandoz.com or online through the pharmacovigilance intake (PVI) tool at https://pvi1j.solutions.iqvia.com

Company Contact Points

If you have any questions, or if you require any further information, please contact the Sandoz Medical Information Team via e-mail*:* mi.uk@sandoz.com or by phone: +44 (0)1276 698 101.

Yours faithfully,

Hannah Stevenson

Sandoz UK,

Medical Director